longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

MDXG

MDXG
----

LongbridgeAI

03:59 ETShareholder Alert: Ademi LLP investigates whether Sanara MedTech Inc. is obtaining a Fair Price for Public Shareholders

prnewswire
Jul 30, 2026 at 08:00 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Ademi LLP is investigating Sanara MedTech Inc. (Nasdaq: SMTI) for potential breaches of fiduciary duty regarding its merger with MiMedx. The firm questions if public shareholders are receiving a fair price, noting insiders receive substantial benefits while the deal imposes penalties on competing bids. Shareholders can join the investigation to seek additional information.

, /PRNewswire/ -- Ademi LLP is investigating Sanara (Nasdaq: SMTI) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with MiMedx.

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

Sanara shareholders will receive $33.00 in cash and 0.4735 shares of MIMEDX common stock for each share of Sanara common stock they own, which represents a value of $2.00 per share, calculated based on the average closing price of MIMEDX common stock of $4.22 for the last five consecutive trading days through and including July 28, 2026, in a cash-and-stock transaction valued at $35 per share, with a total enterprise value of approximately $350 million.

Sanara insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Sanara by imposing a significant penalty if Sanara accepts a competing bid. We are investigating the conduct of the Sanara board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP

Login to unlock1,030characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

Sanara Medtech

Sanara Medtech

USSMTI

+0.17%

MiMedx

MiMedx

USMDXG

+1.53%